How to buy ADC Therapeutics stock | $28.29

ADC Therapeutics SA is a biotechnology business based in the US. ADC Therapeutics shares (ADCT) are listed on the NYSE and all prices are listed in US Dollars. ADC Therapeutics employs 208 staff and has a trailing 12-month revenue of around 0.00.

ADC Therapeutics stock price (NYSE: ADCT)

Use our graph to track the performance of ADCT stocks over time.

ADC Therapeutics shares at a glance

• Key figures

Information last updated 2021-09-19.

Latest market close	$28.29
52-week range	$20.01 - $46.20
50-day moving average	$26.67
200-day moving average	$24.39
Wall St. target price	$43.83
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.67

Buy ADC Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ADC Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ADC Therapeutics price performance over time

Historical closes compared with the close of $28.29 from 2021-09-24

1 week (2021-09-17)	-1.98%
1 month (2021-08-25)	9.40%
3 months (2021-06-25)	12.80%
6 months (2021-03-25)	7.12%

1 year (2020-09-25)	-15.75%
2 years (2019-09-21)	N/A
3 years (2018-09-21)	N/A
5 years (2016-09-21)	N/A

ADC Therapeutics financials

Revenue TTM	$3.8 million
Gross profit TTM	$-141,816,000
Return on assets TTM	-40.47%
Return on equity TTM	-91.02%
Profit margin	0%
Book value	$3.18
Market capitalisation	$2.3 billion

TTM: trailing 12 months

Shorting ADC Therapeutics shares

There are currently 6.0 million ADC Therapeutics shares held short by investors – that's known as ADC Therapeutics's "short interest". This figure is 11.2% up from 5.4 million last month.

There are a few different ways that this level of interest in shorting ADC Therapeutics shares can be evaluated.

ADC Therapeutics's "short interest ratio" (SIR)

ADC Therapeutics's "short interest ratio" (SIR) is the quantity of ADC Therapeutics shares currently shorted divided by the average quantity of ADC Therapeutics shares traded daily (recently around 301907.22528851). ADC Therapeutics's SIR currently stands at 19.93. In other words for every 100,000 ADC Therapeutics shares traded daily on the market, roughly 19930 shares are currently held short.

However ADC Therapeutics's short interest can also be evaluated against the total number of ADC Therapeutics shares, or, against the total number of tradable ADC Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ADC Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 ADC Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.2042% of the tradable shares (for every 100,000 tradable ADC Therapeutics shares, roughly 204 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ADC Therapeutics.

Find out more about how you can short ADC Therapeutics stock.

ADC Therapeutics share dividends

We're not expecting ADC Therapeutics to pay a dividend over the next 12 months.

ADC Therapeutics overview

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B. V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. .

Frequently asked questions

What percentage of ADC Therapeutics is owned by insiders or institutions?
Currently 51.352% of ADC Therapeutics shares are held by insiders and 44.423% by institutions. How many people work for ADC Therapeutics?
Latest data suggests 208 work at ADC Therapeutics. When does the fiscal year end for ADC Therapeutics?
ADC Therapeutics's fiscal year ends in September. Where is ADC Therapeutics based?
ADC Therapeutics's address is: Biopole, Epalinges, Switzerland, 1066 What is ADC Therapeutics's ISIN number?
ADC Therapeutics's international securities identification number is: CH0499880968